[1]张 印,张 军.进展期胃癌淋巴结清扫研究进展[J].医学信息,2019,(07):57-59.[doi:10.3969/j.issn.1006-1959.2019.07.018]
 ZHANG Yin,ZHANG Jun.Progress in Lymph Node Dissection of Advanced Gastric Carcinoma[J].Medical Information,2019,(07):57-59.[doi:10.3969/j.issn.1006-1959.2019.07.018]
点击复制

进展期胃癌淋巴结清扫研究进展()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年07期
页码:
57-59
栏目:
综述
出版日期:
2019-04-01

文章信息/Info

Title:
Progress in Lymph Node Dissection of Advanced Gastric Carcinoma
文章编号:
1006-1959(2019)07-0057-04
作者:
张 印张 军
(重庆医科大学附一院胃肠外科,重庆 400042)
Author(s):
ZHANG YinZHANG Jun
(Department of Gastroenterology,the First Affiliated Hospital of Chongqing Medical University, Chongqing 400042,China)
关键词:
胃癌淋巴结清扫手术范围
Keywords:
Gastric carcinomaLymph node dissectionScope of surgery
分类号:
R73;R81
DOI:
10.3969/j.issn.1006-1959.2019.07.018
文献标志码:
A
摘要:
胃癌的手术范围在过去30年里一直存在争议,关于淋巴结清扫范围的选择、是否需常规联合胰尾/脾脏、腹主淋巴结清扫及其对患者生存获益的利弊一直是胃肠外科研究方向。本文结合国内外相关研究,通过比较不同淋巴结清扫范围并发症发生率、疾病特异性病死率、长期生存获益等差异,总结出较优方案,旨在为临床提供一定理论参考。
Abstract:
The surgical scope of gastriccarcinoma has been controversial for the past 30 years. The choice of lymph node dissection, the need for routine combination of pancreatic tail/spleen, abdominal main lymph node dissection and its pros and cons to benefit patients have been a gastrointestinal surgery studydirection. In this paper, combined with relevant research at home and abroad, by comparing the differences in the incidence of complications of different lymph node dissection, disease-specific mortality, long-term survival benefit, and summarizing the better program, the aim is to provide a theoretical reference for clinical.

参考文献/References:


[1]Torre LA,Siegel RL,Ward EM,et al.Global Cancer Incidence and Mortality Rates and Trends-An Update[J].Cancer Epidemiol Biomarkers Prev,2016,25(1):16-27.
[2]Saito S,Azumi M,Muneoka Y.Cost-effectiveness of combined serum anti-Helicobacter pylori IgG antibody and serum pepsinogen concentrations for screening for gastric cancer risk in Japan[J].The European Journal of Health Economics,2018,19(4):545-555.
[3]Kajitani T.The general rules for the gastric cancer study in surgery and pathology[J].The Japanese Journal of Surgery,1981,11(2):127-139.
[4]Zhang S,Wu L,Wang X,et al.Satisfactory surgical outcome of T2 gastric cancer after modified D2 lymphadenectomy[J].Chinese Journal of Cancer Research,2017,29(2):100-108.
[5]Huang YL,Lin HG,Yang JW,et al.Laparoscopy-assisted versus open gastrectomy with D2 lymph node dissection for advanced gastric cancer: a meta-analysis[J].International Journal of Clinical & Experimental Medicine,2014,7(6):1490-1499.
[6]梁寒.第15版日本《胃癌处理规约》及第5版《胃癌治疗指南》部分内容解读——“第90届日本胃癌学会年会”报道[J].中国实用外科杂志,2018,38(4):391-395.
[7]Papenfuss WA,Kukar M,Oxenberg J,et al.Morbidity and Mortality Associated with Gastrectomy for Gastric Cancer[J].Annals of Surgical Oncology,2014,21(9):3008-3014.
[8]吴晓明,韩华,黄光钺,等.全胃切除术与近端胃大部切除术治疗贲门癌疗效比较[J].新乡医学院学报,2018,35(10):914-917.
[9]Zhou D,Quan Z,Wang J,et al.Laparoscopic-Assisted Versus Open Distal Gastrectomy with D2 Lymph Node Resection for Advanced Gastric Cancer: Effect of Learning Curve on Short-Term Outcomes. A Meta-analysis[J].Journal of Laparoendoscopic & Advanced Surgical Techniques,2014,24(3):139-150.
[10]Cuschieri A,Fayers P,Fielding J,et al.Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial[J].The Surgical Cooperative Group Lancet,1996(347):995-999.
[11]Cuschieri A,Weeden S,Fielding J,et al.Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial[J].Surgical Co-operative Group Br J Cancer,1999(79):1522-1530.
[12]Bonenkamp JJ,Hermans J,Sasako M,et al.Extended lymph-node dissection for gastric cancer[J].N Engl J Med,1999(340):908-914.
[13]Degiuli M,Sasako M,Calgaro M,et al.Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial[J].Eur J Surg Oncol,2004(30):303-308.
[14]Wu CW,Hsiung CA,Lo SS,et al.Nodal dissection for patients with gastric cancer: a randomised controlled trial[J].The Lancet Oncology,2006,7(4):309-315.
[15]Sasako M,Sano T,Yamamoto S,et al.D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer[J].N Engl J Med,2008(359):453-462.
[16]Hartgrink HH,van de Velde CJ,Putter H,et al.Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial[J].J Clin Oncol 2004(22):2069-2077.
[17]Songun I,Putter H,Kranenbarg EM,et al.Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial[J].Lancet Oncol,2010(11):439-449.
[18]丁波,李忠,刘元直.进展期胃癌根治术中脾门淋巴结清扫的临床意义[J].中国普通外科杂志,2014,23(1):133-135.
[19]何裕隆.胃癌根治术中联合胰腺、脾脏切除的问题[J].外科理论与实践,2008,13(1):9-11.
[20]刘启领.胃癌根治术联合脾脏切除治疗胃癌的Meta分析[J].胃肠病学和肝病学杂志,2016,25(8):917-920.
[21]Dassen AE,Lemmens VE,van de Poll-Franse LV,et al.Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007:a population-based study in the Netherlands[J]. Eur J Cancer,2010,46(6):1101-1110.
[22]Ebinger SM,René Warschkow,Tarantino I,et al.Modest overall survival improvements from 1998 to 2009 in metastatic gastric cancer patients:a population-based SEER analysis[J].Gastric Cancer,2016,19(3):723-734.

相似文献/References:

[1]尹晓华,刘重元,黄 琳,等.胃癌中lncRNAs的研究进展[J].医学信息,2018,(03):10.[doi:10.3969/j.issn.1006-1959.2018.03.004]
 YIN Xiao-hua,LIU Zhong-yuan,HUANG Lin,et al.Research Progress of lncRNAs in Gastric Cancer[J].Medical Information,2018,(07):10.[doi:10.3969/j.issn.1006-1959.2018.03.004]
[2]芮昆昆,章 波,邰小华,等.基质金属蛋白酶2与蛋白磷酸酶2A的癌性抑制因子在胃癌中的研究进展[J].医学信息,2018,(03):21.[doi:10.3969/j.issn.1006-1959.2018.03.007]
 RUI Kun-kun,ZHANG Bo,TAI Xiao-hua,et al.The Research Progress of Matrix Metalloproteinase 2 and Cancer Inhibitor of Protein Phosphatase 2A in Gastric Cancer[J].Medical Information,2018,(07):21.[doi:10.3969/j.issn.1006-1959.2018.03.007]
[3]段 巍.1例晚期胃癌化疗并发嗜血细胞综合征患者的护理[J].医学信息,2018,(10):181.[doi:10.3969/j.issn.1006-1959.2018.10.063]
 DUAN Wei.Nursing Care of a Case of Advanced Gastric Carcinoma with Hemophagocytic Syndrome after Chemotherapy[J].Medical Information,2018,(07):181.[doi:10.3969/j.issn.1006-1959.2018.10.063]
[4]潘理会,李育庄,李春辉.胃癌与高凝血状态关系的研究现状[J].医学信息,2018,(11):15.[doi:10.3969/j.issn.1006-1959.2018.11.005]
 PAN Li-hui,LI Yu-zhuang,LI Chun-hui.Research Status of the Relationship between Gastric Carcinoma and Hypercoagulable State[J].Medical Information,2018,(07):15.[doi:10.3969/j.issn.1006-1959.2018.11.005]
[5]梁延洋,程艳娜,华柏慧,等.胃癌合并2型糖尿病术后血糖改善的临床观察[J].医学信息,2018,(17):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
 LIANG Yan-yang,CHENG Yan-na,HUA Bai-hui,et al.Clinical Observation of Postoperative Blood Glucose Improvement in Patients with Gastric Cancer Complicated with Type 2 Diabetes Mellitus[J].Medical Information,2018,(07):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
[6]林跃韩,许庆文.腹腔镜uncut Roux-en-Y吻合与传统吻合方式的研究进展[J].医学信息,2018,(22):31.[doi:10.3969/j.Ⅰssn.1006-1959.2018.22.010]
 LIN Yue-han,XU Qing-wen.Research Progress of Laparoscopic uncut Roux-en-Y Anastomosis and Traditional Anastomosis[J].Medical Information,2018,(07):31.[doi:10.3969/j.Ⅰssn.1006-1959.2018.22.010]
[7]马玉涛,石文娜,李晓林,等.免疫荧光法检测FSHR与GnRHR在胃癌组织中的分布及其共定位研究[J].医学信息,2018,(23):79.[doi:10.3969/j.issn.1006-1959.2018.23.022C]
 MA Yu-tao,SHI Wen-na,LI Xiao-lin,et al.Study on the Distribution and Co-localization of FSHR and GnRHR in Gastric Cancer Tissues by Immunofluorescence Assay[J].Medical Information,2018,(07):79.[doi:10.3969/j.issn.1006-1959.2018.23.022C]
[8]赵 静.血浆纤维蛋白原和CA724水平在胃癌患者的变化及临床意义[J].医学信息,2018,(24):82.[doi:10.3969/j.issn.1006-1959.2018.24.021]
 ZHAO Jing.Changes and Clinical Significance of Plasma Fibrinogen and CA724 Levels in Patients with Gastric Cancer[J].Medical Information,2018,(07):82.[doi:10.3969/j.issn.1006-1959.2018.24.021]
[9]万 芳.以贫血为首发症状的消化道恶性肿瘤临床分析[J].医学信息,2018,(24):175.[doi:10.3969/j.issn.1006-1959.2018.24.054]
 WAN Fang.Clinical Analysis of Digestive Tract Malignancies with Anemia as the First Symptom[J].Medical Information,2018,(07):175.[doi:10.3969/j.issn.1006-1959.2018.24.054]
[10]牛 悦,白建平,卢建跃.HER-2阳性胃癌的研究进展[J].医学信息,2019,(01):44.[doi:10.3969/j.issn.1006-1959.2019.01.015]
 NIU Yue,BAI Jian-ping,LU Jian-yue.Progress in Research of HER-2 Positive Gastric Cancer[J].Medical Information,2019,(07):44.[doi:10.3969/j.issn.1006-1959.2019.01.015]

更新日期/Last Update: 2019-04-01